# Ankuo Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ankuo-medicine

- Industry: Healthcare Specialists
- Headquarters: Shanghai, China
- Total disclosed funding: $35M
- Latest round: Series A (Apr 1, 2021)
- Investors on record: 6

## About

Established in 2019 and based in Shanghai, China, Ankuo Medicine is a medicine developer that focuses on the development and research of oncology supportive care. In April 2021, the company closed a series A funding. Ankuo Medicine's drug candidate product portfolio development aims to solve the skin toxicity caused by cancer therapy. OQL011 is a topical ointment for the treatment of moderate to severe hand-foot-skin reaction (HFSR). It is currently undergoing a multi-center, randomized, phase 2 clinical trial in the United States. In addition, Ankuo Medicine is developing two other tumor dermatological drugs. In addition to the oncology dermatology product portfolio, the company has also developed other targeted cancer support care agents aimed at addressing the gastrointestinal and bone marrow toxicity caused by chemotherapy, HER2/EGFR targeted cancer therapy and immuno-oncology agents. The company generates revenue through the sales of its oncology drugs. In the future, the company will advance the ongoing phase 2 clinical trials of the lead compound OQL011, and a number of other targeted cancer support care plans that are expected to enter different stages of clinical development.

## Funding rounds

- Series A, Apr 1, 2021, $20M — Sinovation Ventures, CASH Capital, Frees Fund, MPC, BioTrack Capital, Shiyu Capital
- Series A, Oct 28, 2019, $15M — CASH Capital, MPC, BioTrack Capital

## Investors

- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Series A
- MPC — Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A
- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Series A
- Frees Fund (https://capitalatlas.ai/funds/frees-fund) — Series A
- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Series A